Miracle Anti-HIV Drug Lenacapavir Is Being Wasted by the Trump Administration

Over the past two decades, the global distribution and easy access to antiviral drugs (ARV) has turned HIV from the death penalty to control and tens of millions of new infections when used as pre -exposure (Prep). The wonderful new drug Lenacapavir is the ARV novel, the first of its class to target HIV capsule, which is a viral gymnasium. Capsid is undergoing a process called Uncoating, which allows the repetition of viral genome and the production of new virus molecules. Lenacapavir prevents both unquestible new viruses. Due to the extent to which the HIV protein is linked tightly, which disrupts its ability to work normally, it is difficult for the virus to develop resistance.

Lenacapavir is not only the new hot ARV in the city, but also exceeds all other drugs in the market in terms of their durability. When Lenacapavir is injected under the skin, it crystallizes and then releases it slowly over months, providing sustainable protection against HIV infection. It is not necessary to be taken orally every day, making it more practical and less stigma than the current preparatory systems, especially for women, who often face social or cultural pressures that discourage the use of condoms or preparatory tablets by mouth.

Over the past two decades, the global distribution and easy access to antiviral drugs (ARV) has turned HIV from the death penalty to control and tens of millions of new infections when used as pre -exposure (Prep). The wonderful new drug Lenacapavir is the ARV novel, the first of its class to target HIV capsule, which is a viral gymnasium. Capsid is undergoing a process called Uncoating, which allows the repetition of viral genome and the production of new virus molecules. Lenacapavir prevents both unquestible new viruses. Due to the extent to which the HIV protein is linked tightly, which disrupts its ability to work normally, it is difficult for the virus to develop resistance.

Lenacapavir is not only the new hot ARV in the city, but also exceeds all other drugs in the market in terms of their durability. When Lenacapavir is injected under the skin, it crystallizes and then releases it slowly over months, providing sustainable protection against HIV infection. It is not necessary to be taken orally every day, making it more practical and less stigma than the current preparatory systems, especially for women, who often face social or cultural pressures that discourage the use of condoms or preparatory tablets by mouth.

Clinical experiments have shown that Lenacapavir prevents HIV in 99.9 per cent of people receiving only two shots annually as preparation. It shows a great promise to treat multiple drug -resistant infections, as well, while giving hope to patients with treatment options. Lenacapavir is preparing to deal with an overwhelming kicks of HIV by treating infections that have not been treated previously and new prevention – but only as long as it is available, which is now at risk.

The use of Arvs was highly dependent on the United States Agency for International Development (the United States Agency for International Development) and the Pepfar Emergency Emergency Plan. Investments by the American Agency for International Development and Pepfar in critical infrastructure, clinical expertise, health care and expanded access to ARVS all over the world. Their budgets have reached an approximation of the US spending, but it has returned a huge value: 26 million life provided by supporting ARV treatment, which is approximately 70 percent of people receiving HIV treatment worldwide.

In Pepfar countries, new HIV infections have decreased by more than 50 percent. AIDS deaths fell more. Nearly 8 million children were born with HIV thanks to these programs, which increased the average life expectancy for almost 20 years in some places. They were also responsible for more than 90 percent of preparatory initiatives, while protecting more than 2.5 million people from HIV infection as a result. When Lenacapavir came at the scene of the accident, it was immediately clear that it could have a revolution in preparatory by taking advantage of what the United States Agency for International Development and Pepfar created.

The US Food and Drug Administration approved LenacAPAVIR to prepare in June. In any other circumstances, this will be a reason to celebrate – but not in the current political scene of the United States. Pepfar has maintained catastrophic devastating cuts, while the United States Agency for International Development has been dismantled to the heart. These discounts forced clinics to close, remove health care workers from work, and most importantly, caused the exit from ARV.

The countries that received Pepfar have faced an accelerated economic growth as a result of reducing HIV mortality in its operating bases. With the return of HIV -related deaths to these countries, as well as the support of the United States, will suffer its economies, which will increase the erosion and availability of national health care resources.

This is very bad news for Lenacapavir capabilities to bring a coup to HIV. Revolutionary new drugs only work if the people they need them can get them. Without Pepfar and USAID infrastructure, millions of people at risk of HIV will lack life -saving medications.

When combined with a lack of access to ARV medications, drug HIV strains are likely to appear, because this is the known result of incomplete commitment to daily treatment systems. This can contribute to the scene of HIV more clearly than Pepfar: HIV mortality will increase and return to pre -environmental levels, except that they will now cause viruses that are difficult to treat and easy to spread.

Another issue related to costs. The manufacturer of Lenacapavir, Gilead, provided the drug with a gradient pricing system costing $ 28,000 a year for preparation and $ 42,000 annually to treat HIV. Studies that can be manufactured can be manufactured by a year for up to $ 25 a year, prompting the United Nations AIDS to urge Gilead to reduce their prices. This reminds us of the time before PePFAR, when people in archaeological countries were able to reach ARV treatments while millions of people died in the global south because of AIDS.

Although Gilead has developed a “unbearable” model to grant non -exclusive and free licenses to manufacture Lenacapavir as a general drug in low and medium -income countries, the cost of production is still high. “Non -profit” pricing excludes many medium -income countries in Latin America, where HIV infection increases. Pepfar and USID dismantling will be possible to access Lenacapavir and other ARVs in these countries, which leads to a completely new scene of countries that are unable to stop HIV infection. Without associated investments in infrastructure, training and health systems, millions of HIV will suffer from another reason other than non -short American policy makers.

In the United States, the Director of National Health Institutes (NIH) is Jay Bhateraya ideas for integrating Lenacapavir into public health policies for the prevention of HIV. Bhattacharlya has launched a plan to perpetuate one billion dollars to implement the Lenacapavir Preparatory at the country level. However, this would strip the funding of other HIV research programs, such as research funded by the National Institutes of Health that led to the discovery of Lenacapavir in the first place, as well as the research of HIV vaccine that US Minister of Health and Humanitarian Services Robert F. Kennedy Junior. The losses of additional jobs resulting from the Trump administration, which are separated from the entire research and implementation programs-both of them inside and outside the government-will lead to reducing the ability of the national health institutes to support national access to the Lenacapavir Preparatory.

Since the Trump administration is the dismantling of biomedics and public health health in the United States, and thus hinders the efforts to combat HIV worldwide, it becomes increasingly difficult to understand how Bahtasheria’s plan to cancel Lenacapavir insurance will significantly reduce the burden of HIV locally, and less than the end of the world.

Pepfar was established by former US President George W. Bush, a conservative Republican viewed as an ethical necessity for the United States to contribute to global health. It is clear that the Trump administration does not consider itself responsible for the previous obligations towards the world or even the Americans.

It is a profound and profound tragic that the United States deliberately abandoned its battle against HIV at the same time as a drug that changes the game appears like Lenacapavir in the market. It is not clear that any other country has money, freedom, infrastructure, or national sense of moral commitment to filling the void.